SCHEMBL259283

SCHEMBL259283

Cn1cc(-c2ccccc2)nc1C=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 6/20 0.48
BRD4 O60885 2/20 0.44
ALDH1A1 P00352 7/20 0.42
KDM4E B2RXH2 6/20 0.42
MAPT P10636 3/20 0.41
PKM P14618 3/20 0.41
TP53 P04637 3/20 0.40
HPGD P15428 3/20 0.40
TSHR P16473 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
HSD17B10 Q99714 3/20 0.40
KMT2A Q03164 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
CDK5 Q00535 1/20 0.40
CDK5R1 Q15078 1/20 0.40
TLR8 Q9NR97 2/20 0.40
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12641898 0.84 RAB9A (0.46) PDE10AALDH1A1KDM4EMAPTTP53
SCHEMBL2042236 0.83 PDE10A (0.54) PDE10AALDH1A1TLR8
SCHEMBL31326500 0.83 PTGS1 (0.42) PDE10AALDH1A1KDM4EMAPTHPGD
SCHEMBL12641920 0.83 TLR8 (0.43) PDE10AALDH1A1KDM4EMAPTPKM
SCHEMBL24712796 0.81 PDE10A (0.53) PDE10ABRD4ALDH1A1KDM4EMAPT
SCHEMBL20123855 0.79 ALDH1A1 (0.41) ALDH1A1KDM4EMAPTPKMTP53
SCHEMBL7512631 0.77 PDE10A (0.45) PDE10APKMNPC1RAB9A
SCHEMBL6902589 0.77 PDE10A (0.52) PDE10AALDH1A1HSD17B10ADORA2A
SCHEMBL2037136 0.77 PDE10A (0.52) PDE10AADORA2AADORA1
SCHEMBL24567427 0.77 PDE10A (0.44) PDE10ABRD4ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113164459-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-03 CN claimed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
US-20240336593-A1 Compound Having Antitumor Activity And Use Thereof INNOVSTONE THERAPEUTICS LIMITED (CN) 2024-10-10 US disclosed
CN-113164459-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-03 CN disclosed
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 US disclosed
EP-4209485-A1 COMPOUND HAVING ANTITUMOR ACTIVITY AND USE THEREOF Innovstone Therapeutics Limited (CN) 2023-07-12 EP disclosed
EP-4209485-A1 COMPOUND HAVING ANTITUMOR ACTIVITY AND USE THEREOF Innovstone Therapeutics Limited (CN) 2023-07-12 EP disclosed
CN-116113626-A Compound with anti-tumor activity and application thereof 上海翊石医药科技有限公司 2023-05-12 CN disclosed
US-20230145249-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 US disclosed
US-20220332713-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2022-10-20 US disclosed
WO-2009051718-A2 CALCIUM RECEPTOR MODULATING AGENTS AMGEN INC. (US) 2009-04-23 WO disclosed
US-20080269443-A1 Methods of oligomerizing olefins EXXONMOBIL CHEMICAL PATENTS INC. 2008-10-30 US disclosed
US-20080269443-A1 Methods of oligomerizing olefins EXXONMOBIL CHEMICAL PATENTS INC. 2008-10-30 US disclosed
US-7414006-B2 Methods for oligomerizing olefins EXXONMOBIL CHEMICAL PATENTS INC. (US) 2008-08-19 US disclosed
US-7414006-B2 Methods for oligomerizing olefins EXXONMOBIL CHEMICAL PATENTS INC. (US) 2008-08-19 US disclosed
US-7368578-B2 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-06 US disclosed
US-20060135578-A1 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 US disclosed
EP-1541564-A1 FIVE-MEMBERED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed
US-5015473-A Beta-lactamase inhibitors PFIZER INC. (US) 1991-05-14 US disclosed
US-4826833-A ANTIBIOTICS PFIZER INC. (US) 1989-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332713-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP PDE10A 594/4885BRD4 1669/4885ALDH1A1 312/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH PDE10A 1367/4885BRD4 2258/4885ALDH1A1 587/4885
US-20230145249-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP PDE10A 594/4885BRD4 1669/4885ALDH1A1 312/4885
US-20240336593-A1 Compound Having Antitumor Activity And Use Thereof PRMT5, PRMT1, PRMT6 PDE10A 2479/4885BRD4 175/4885ALDH1A1 3912/4885
US-20060135578-A1 Five-membered heterocyclic compounds GPR119, OR10J3, CYP11B1 PDE10A 1262/4885BRD4 1002/4885ALDH1A1 821/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP PDE10A 594/4885BRD4 1669/4885ALDH1A1 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.